Empowered Patient Podcast

Mel Kaspin Blume is a copywriter and storyteller and the author of Screens, Beans and Quarantines, a free downloadable children's book addressing the questions kids have about the impact of COVID-19. With a six year old daughter and three year old son, Mel decided to make up a story to help parents open up the conversation with their kids about the changes in their lives. Mel also shares how her previous work as Head of Copy at Disney Consumer Products informs her ability to get the attention of both kids and parents with relevant short and snappy dialogue.

#COVID19

OnceUponABlume.com

Listen to the podcast here

Mel Kaspin Blume is a copywriter and storyteller and the author of Screens, Beans and Quarantines, a free downloadable children's book addressing the questions kids have about the impact of COVID-19. With a six year old daughter and three year old son, Mel decided to make up a story to help parents open up the conversation with their kids about the changes in their lives. Mel also shares how her previous work as Head of Copy at Disney Consumer Products informs her ability to get the attention of both kids and parents with relevant short and snappy dialogue.

#COVID19

OnceUponABlume.com

Download the transcript here

Pascal Descargues PhD, Founder and CEO, Genoskin talks about bringing the only living injectable human platform to the market to enable clinical testing of drugs for efficacy and toxicity by biotech and pharmaceutical companies. Their standardized platform uses real human skin tissue to test the consequences of drugs administered topically or injected in the skin. Currently Genoskin is also looking at using their platform to test the immunological signature induced by a COVID-19 vaccine candidate to predict if a vaccine can be effective.

@genoskin #genoskin #skin #drugtesting #vaccines #clinicaltesting

Genoskin.com

Listen to the podcast here

Pascal Descargues PhD, Founder and CEO, Genoskin talks about bringing the only living injectable human platform to the market to enable clinical testing of drugs for efficacy and toxicity by biotech and pharmaceutical companies. Their standardized platform uses real human skin tissue to test the consequences of drugs administered topically or injected in the skin. Currently Genoskin is also looking at using their platform to test the immunological signature induced by a COVID-19 vaccine candidate to predict if a vaccine can be effective.

@genoskin #genoskin #skin #drugtesting #vaccines #clinicaltesting

Genoskin.com

Download the transcript here.

Jens Hennecke, Chief Business Officer, SOTIO explains how this biotech company is developing the next generation of immunotherapies with a focus on a new compound called SO-C101 based on the cytokine IL-15, the key cytokine that activates T-cells and NK cells. In clinical trials, this drug, a modified IL-15 does not cause unwanted side effects like similar products to treat solid tumors and is a superagonist with a much better potency to activate memory T-cells, cytotoxic T-cells and NK cells.

#SOTIO #immunotherapies #IL15

SOTIO.com

Listen to the podcast here

Jens Hennecke, Chief Business Officer, SOTIO explains how this biotech company is developing the next generation of immunotherapies with a focus on a new compound called SO-C101 based on the cytokine IL-15, the key cytokine that activates T-cells and NK cells. In clinical trials, this drug, a modified IL-15 does not cause unwanted side effects like similar products to treat solid tumors and is a superagonist with a much better potency to activate memory T-cells, cytotoxic T-cells and NK cells.

#SOTIO #immunotherapies #IL15

SOTIO.com

Download the transcript here

Steven M. Fruchtman, M.D., President and Chief Executive Officer, Onconova Therapeutics discusses Rigosertib, a drug that has the potential to downregulate the RAS pathway, the most commonly mutated gene in cancer. Rigosertib is a proprietary phase 3 small molecule, currently being evaluated in second-line treatment of patients with higher-risk myelodysplastic syndrome (MDS) and refractory higher-risk MDS patients. Also known as pre-leukemia, MDS is a cancer of the bone marrow stem cell and the mission of Onconova is to prolong the lives of those suffering from this disease.

@Onconova_ONTX

#cancer #oncology #RAS #MDS #PreLeukemia #Leukemia $ONTX

Onconova.com

Listen to the podcast here

Steven M. Fruchtman, M.D., President and Chief Executive Officer, Onconova Therapeutics discusses Rigosertib, a drug that has the potential to downregulate the RAS pathway, the most commonly mutated gene in cancer. Rigosertib is a proprietary phase 3 small molecule, currently being evaluated in second-line treatment of patients with higher-risk myelodysplastic syndrome (MDS) and refractory higher-risk MDS patients. Also known as pre-leukemia, MDS is a cancer of the bone marrow stem cell and the mission of Onconova is to prolong the lives of those suffering from this disease.

@Onconova_ONTX

#cancer #oncology #RAS #MDS #PreLeukemia #Leukemia $ONTX

Onconova.com

Download the transcript here

Elizabeth Jeffords, Chief Commercial and Strategy Officer and Eva Czirr, Associate Director, Alkahest talk about how they are applying their expertise in age-related and neurodegenerative and cognitive diseases to treating chronic kidney disease particularly end stage renal disease. With a focus on cognitive impairment related to inefficient dialysis, Alkahest is decoding the protein beta-2 microglobulin to determine if alleviation of a massive overload of the protein can benefit patients.

@alkahestinc #CKD #ESRD #B2M

Alkahest.com

Listen to the podcast here

Elizabeth Jeffords, Chief Commercial and Strategy Officer and Eva Czirr, Associate Director, Alkahest talk about how they are applying their expertise in age-related and neurodegenerative and cognitive diseases to treating chronic kidney disease particularly end stage renal disease. With a focus on cognitive impairment related to inefficient dialysis, Alkahest is decoding the protein beta-2 microglobulin to determine if alleviation of a massive overload of the protein can benefit patients.

@alkahestinc #CKD #ESRD #B2M

Alkahest.com

Download the transcript here